Open AccessAn investigation of the pharmacokinetics of topical Lamisil® 1% cream
Author(s) -
Stéphanie Hill,
Robert Thomas,
Stephen G. Smith,
A.Y. Finlay,
Stéphanie Hill,
Robert Thomas,
Stephen G. Smith,
A.Y. Finlay
Publication year - 2011
Publication title -
vestnik dermatologii i venerologii
Language(s) - English
Resource type - Journals
eISSN - 2313-6294
pISSN - 0042-4609
DOI - 10.25208/vdv1036
Subject(s) - stratum corneum , pharmacokinetics , cmax , medicine , dermatology , pharmacology , pathology
Twenty volunteers were entered into a study to investigate the pharmacokinetics of Lamisil® 1% cream. The subjects wererandomized to receive Lamisil® 1% cream applied to the skin on the back on 1 day, or on 3, 5 or 7 consecutive days.Up to five biopsies were taken at a site on the upper back at various time-points both during treatment and aftertreatment. Lamisil® levels in the biopsies were analyzed using HPLC.The study showed that increasing the number of applications from one to seven did not significantly increase the peakconcentration (Cmax) in the stratum corneum.However, there was an increase in the total amount of Lamisil® found in the stratum corneum resulting in Lamisil® beingdetected for longer periods after cessation of therapy.Treatment for 7 days resulted in Lamisil® still being detectable 7 days after cessation of therapy, and the drugconcentration was significantly higher than the concentration killing the common causative organisms of superficialdermatomycoses.This study indicates a significant potential for short-term treatment with Lamisil® 1% cream in superficialdermatomycoses.